國家衛生研究院 NHRI:Item 3990099045/6889
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 859776      線上人數 : 829
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/6889


    題名: Overexpression of galectin-9 in islets prolongs grafts survival via downregulation of Th1 responses
    作者: Chou, FC;Kuo, CC;Wang, YL;Lin, MH;Yen, BL;Chang, DM;Sytwu, HK
    貢獻者: Institute of Cellular and Systems Medicine
    摘要: The differential activation of T helper (Th) cells and production of cytokines contribute to graft rejection or tolerance. In general, the Th1-type cytokines and cytotoxic T cells are detected consistently in host undergoing rejection, whereas Th2 responses are linked to a tolerance condition. Galectin-9 modulates Th1 cell immunity by binding to the T-cell immunoglobulin mucin-3 (Tim-3) molecule expressed on the Th1 cells. We investigate whether overexpression of galectin-9 in islets prolongs grafts survival in diabetic recipients. Islets were transduced with lentiviruses carrying galectin-9 and were then transplanted to streptozotocin-induced diabetic NOD/SCID recipients. The normoglycemic recipients then received splenocytes from diabetic NOD mice. Blood glucose concentration was monitored daily after adoptive transfer. The histology of the islet grafts and flow cytometric analyses were assessed at the end of the study. Overexpression of galectin-9 in islets prolonged grafts survival in NOD/SCID mice after challenge with diabetogenic splenocytes (mean graft survival, 38.5 vs 26.0 days, n = 10, respectively; P = 0.0096). The galectin-9-overexpressed grafts showed decreased infiltration of IFN-gamma-producing CD4(+) and CD8(+) T cells, but not of IL-17-producing CD4(+) T cells. Strikingly, this islet-specific genetic manipulation did not affect the systemic lymphocyte composition, indicating that galectin-9 may regulate T cellmediated inflammation in situ. We demonstrate that galectin-9 protects grafts from Th1- and Tc1-cell-mediated rejections, suggesting that galectin-9 has preventive and/or therapeutic benefit in transplant therapy for autoimmune diabetes and may be applied further to the transplantation of other organs or tissues.
    日期: 2013-11
    關聯: Cell Transplant. 2013 Nov;22(11):2135-2145.
    Link to: http://dx.doi.org/10.3727/096368912x657891
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0963-6897&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000327109200014
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84886424649
    顯示於類別:[顏伶汝] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PB2012120602.pdf487KbAdobe PDF604檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋